Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение лимфомы из клеток мантии

Литература

  1. Bodet-Milin C, Touzeau C, Leux C, Sahin M, et al. Prognostic impact of 18F-fluoro- deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37(9):1633-42
  2. Budde LE, Guthrie KA, Till BG, Press OW et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol. 2011;29(22):3023-9
  3. Del Giudice I, Messina M, Chiaretti S, Santangelo S, et al. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. Br J Haematol. 2012;156(5):601-11
  4. Поддубная И.В. Терапевтичевские проблемы при лимфоме зоны мантии. Современная онкология. 2010;2:48-53
  5. Dietrich S, Tielesch B, Rieger M, et al. Patterns and Outcome of Relapse After Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. Cancer 2010;117(9):1901-10
  6. Dreyling MH, Hoster E, Van Hoof A, et al. Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the European MCL Network. Blood. 2008;112:769
  7. Epner EM, Unger J, Miller T, et al. A multicenter trial of hyper-CVAD-rituxan in patients with newly diagnosed mantle cell lymphoma. Blood. 2007;110:121a. Abstract 387.
  8. Furtado M, Rule S. Indolent mantle cell lymphoma. Haematologica. 2011 Aug;96(8):1086- 8
  9. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355-62
  10. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009 Aug 20;114(8):1469-76
  11. Лорие Ю.Ю., Воробьев В.И. Индукционная терапия лимфомы из клеток зоны мантии. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2011;4(1):10-19
  12. Hermine O, Hoster E, Walewski J, et al. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood. 2010;116:Abstract 110
  13. Hosein PJ, Pastorini VH, Paes FM, et al. Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol. 2011;86(10):841-5
  14. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-565
  15. Kirschey S, Wagner S, Hess G. Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? Clin Med Insights Oncol. 2012;6:153-64
  16. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119(9):2093-9
  17. Le Gouill S, Kröger N, Dhedin N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol. 2012;23(10):2695-2703
  18. Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited stage mantle cell lymphoma: Clinical outcome in patients from British Columbia. Ann Oncol. 2003;14(10):1555-61
  19. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–13.
  20. Mato AR, Svoboda J, Feldman T, et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer. 2012;118(14):3565-3570
  21. Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156(3):346-53
  22. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol. 1989;7(5):365-80
  23. Ondrejka SL, Lai R, Kumar N, et al. Indolent mantle cell leukemia: clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, κ light chain restriction, and good prognosis. Haematologica. 2011;96:1221–7.
  24. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975–81
  25. Romaguera J, Fayad L, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200-8.
  26. Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011;21(5):293-8
  27. Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (International Agency for Research on Cancer (IARC)) 4th ed., 2008.
  28. Tiemann M., Schrader C., Klapper W. et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131(1):29-38.
  29. Visco C, Zambello R, Paolini R, et al. Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen In Patients with Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant. Blood (ASH Annual Meeting Abstracts). 2011;118:2677.
  30. Zhou Y, Wang H, Fang W, et al. Incidence Trends of Mantle Cell Lymphoma in the United States Between 1992 and 2004. Cancer. 2008;113:791–8.
  31. Fenske TS, Carreras J, Zhang M, et al. Outcome of patients with mantle-cell lymphoma undergoing autologous versus reduced-intensity allogenic transplantation. Ann Oncol. 2011;22(Suppl. 4) Abstract018.
  32. Hermine OR, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high-dose Ara-C containing myeloablative regimen and autologous stemm cell transplantation (ASCT) is superior to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: update of results of the MCL Younger trial of the European Mantle Cell Lymphoma Network (MCL NET). Ann Oncol. 2011;22(Suppl 4):Abstract 023.
  33. Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984-92
  34. Kluin-Nelemans J.C., Hoster E., Walewski J, et al. R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118:439
  35. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent and mantle-cell lymphomas: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany) Blood. 2009;114:Abstract 405
  36. Воробьев В.И., Лорие Ю.Ю., Мангасарова Я.К., и соавт. Возможности терапии рецидивов и резистентного течения лимфомы из клеток мантийной зоны. Гематология и трансфузиология. 2011;56(1):34-37
  37. Gill S, Herbert KE, Prince HM, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 2009;147:83-88

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

Литература
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Table of contents

Данный блок поддерживает скрол*